Reduced Pancreatic Polypeptide Secretion in Obese Subjects*

Marco, José; Zulueta, María Ángeles; Correas, Isabel; Villanueva, María Luisa

doi:10.1210/jcem-50-4-744

Cited by 57 publications

(27 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings of decreased fasting PP levels in obese children are in concordance with most studies in obese adults, [19][20][21] whereas only a few studies consisting of a small number of subjects found no difference between lean and obese subjects. [16][17][18] It could be questioned whether low PP levels may contribute to obesity as circulating PP concentrations decrease appetite in humans.…”

Section: Discussionsupporting

confidence: 91%

“…Some studies found no difference between lean and obese subjects, [16][17][18] whereas other studies demonstrated lower fasting PP levels in obese subjects. [19][20][21] If PP levels are decreased in obese subjects, this could reflect a consequence of overweight or, on the other hand, a cause of overweight as PP affect food intake. To differentiate these two possibilities, long-term studies in obese subjects losing weight are necessary.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pancreatic polypeptide in obese children before and after weight loss

et al. 2006

View full text Add to dashboard Cite

Objective: Little is known concerning pancreatic polypeptide (PP) in weight loss and in childhood obesity. Methods: Fasting PP, leptin and insulin concentrations were determined in 38 obese children and compared with 35 lean children of the same age, gender and pubertal stage. Furthermore, changes of PP concentrations over a 1-year period were analyzed in the obese children participating in a weight loss intervention program. Results: Obese children had significantly (Po0.01) lower PP, and higher leptin and insulin levels compared to lean children. In multiple linear regression analysis, PP was significantly negatively correlated to body mass index (Po0.01), but not to leptin, insulin, age, gender and pubertal stage. Changes of PP did not significantly correlate to changes of insulin (r ¼ 0.07, P ¼ 0.343) and leptin (r ¼ À0.02, P ¼ 0.459). The substantial weight loss in 17 children led to a significant (Po0.05) increase in PP and decrease in insulin and leptin. In the 21 children without substantial weight loss, there were no significant changes in PP, insulin and leptin. Conclusions: PP concentrations are decreased in obese children and independent of age, gender, pubertal stage, leptin and insulin. The decrease of PP in obese children normalized after weight loss. Therefore, low PP concentrations reflect the overweight status, rather than cause it.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Pancreatic polypeptide in obese children before and after weight loss

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Perhaps duration of diabetes or age interacting with diabetes relates to these findings in the older subjects. There was no evidence of an effect of adiposity upon fasting plasma levels of PP [18,19].…”

Section: Discussionmentioning

confidence: 76%

The effect of treatment of Type 2 (insulin independent) diabetes mellitus on plasma concentrations of pancreatic polypeptide and glucagon

1981

View full text Add to dashboard Cite

Summary. The effect of the control of diabetes with diet and insulin upon plasma levels of human pancreatic polypeptide and glucagon was determined in eight patients with Type 2 (insulin independent) diabetes mellitus. The mean + SEM fasting plasma glucose was 15.9 _+ 1.3 mmol/1 for 5 days of diet treatment and 5.9 _+ 0.4 mmol/l for the last 5 days of treatment with diet plus insulin (p < 0.0001); corresponding fasting plasma pancreatic polypeptide levels were 328 _+ 97 and 247 + 71 pg/ml (p < 0.05) and immunoreactive glucagon levels were 95 _+ 11 and 62 4-6 pg/ml (p < 0.005). Cooked ground beef was administered on the first day of diet treatment and on the last day of treatment with diet plus insulin; mean maximal rise of pancreatic polypeptide, and total and incremental plasma pancreatic polypeptide response areas were significantly lower following treatment (p < 0.01), as was total area for immunoreactive glucagon (p < 0.05). Normalisation of fasting plasma glucose by short-term treatment with diet plus insulin is associated with decreases in basal and stimulated secretory activity of the pancreatic polypeptide cells in insulin independent diabetes mellitus.

show abstract

“…[6][7][8][9] In developing such ligands, truncated peptide analogues are becoming increasingly popular. For example, [Nle 30 ]hPP [25][26][27][28][29][30][31][32][33][34][35][36] and [Leu 34 ]pNPY [25][26][27][28][29][30][31][32][33][34][35][36] were found to be Y 4 R selective partial agonists, 10 and a nonapeptide based on the C-terminal fragment of NPY, Ile-Asn-Pro-Ile-Tyr-Arg-Leu-Arg- [28][29][30][31][32][33][34][35][36] ], also known as 1229U91, showed enhanced potency at both receptor subtypes but is in particular the most potent known Y 1 R antagonist.…”

Section: Introductionmentioning

confidence: 99%

Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y₄ Receptor Agonist Derived by an Olefin Metathesis Approach

et al. 2016

View full text Add to dashboard Cite

(2016) Optically pure, structural and fluorescent analogues of a dimeric Y4 receptor agonist derived by an olefin metathesis approach. Journal of Medicinal Chemistry . ISSN 1520-4804 Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/34144/1/acs.jmedchem.6b00310.pdf Copyright and reuse:The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions. This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see: http://eprints.nottingham.ac.uk/end_user_agreement.pdf A note on versions:The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.For more information, please contact eprints@nottingham.ac.uk Just Accepted "Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts. 1Optically pure, structural and fluorescent analogues of a dimeric Y 4 receptor agonist derived by an olefin metathesis approach. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59

show abstract

Reduced Pancreatic Polypeptide Secretion in Obese Subjects*

Cited by 57 publications

References 13 publications

Pancreatic polypeptide in obese children before and after weight loss

Pancreatic polypeptide in obese children before and after weight loss

The effect of treatment of Type 2 (insulin independent) diabetes mellitus on plasma concentrations of pancreatic polypeptide and glucagon

Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y₄ Receptor Agonist Derived by an Olefin Metathesis Approach

Contact Info

Product

Resources

About

Reduced Pancreatic Polypeptide Secretion in Obese Subjects*

Cited by 57 publications

References 13 publications

Pancreatic polypeptide in obese children before and after weight loss

Pancreatic polypeptide in obese children before and after weight loss

The effect of treatment of Type 2 (insulin independent) diabetes mellitus on plasma concentrations of pancreatic polypeptide and glucagon

Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y4 Receptor Agonist Derived by an Olefin Metathesis Approach

Contact Info

Product

Resources

About

Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y₄ Receptor Agonist Derived by an Olefin Metathesis Approach